Federal Register of Legislation - Australian Government

Primary content

Specifications as made
This instrument specifies diseases in relation to employment and commences on 1 October 2017 to coincide with the sunsetting of the previous instrument, Safety, Rehabilitation and Compensation (Specified Diseases) Notice 2007 (1), made under s 7(1) of the Safety, Rehabilitation and Compensation Act 1988.
Administered by: Employment
Made 03 Oct 2017
Registered 03 Oct 2017
Tabled HR 16 Oct 2017
Tabled Senate 16 Oct 2017
Table of contents.

 

Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2017

I, Michaelia Cash, Minister for Employment, make the following instrument.

Dated  3 October 2017

Michaelia Cash

Minister for Employment


Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Definitions................................................................................................................................ 1

5  Application............................................................................................................................... 1

6  Schedules................................................................................................................................. 1

7  Specification............................................................................................................................. 1

Schedule 1—Specification                                                                                            2

Schedule 2—Occupational asthma                                                                            10

Schedule 3—Repeals                                                                                                   17

Safety, Rehabilitation and Compensation (Specified Diseases) Notice 2007 (1)                   17


1  Name

                   This instrument is the Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2017.

2  Commencement

                   This instrument commences on the earlier of:

(a)    the day after this instrument is registered on the Federal Register of Legislation; and

(b)   1 October 2017.

3  Authority

                   This instrument is made under paragraph 7(1)(b) of the Safety, Rehabilitation and Compensation Act 1988.

4  Definitions

                   In this instrument:

Act means the Safety, Rehabilitation and Compensation Act 1988.

disease has its ordinary meaning.

substance means any natural or artificial substance, whether in the form of a solid, liquid, gas or vapour.

5  Application

                   This instrument applies in relation to a disease that an employee sustains on or after the day this instrument commences.

6  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

7  Specification

                   For the purposes of paragraph 7(1)(b) of the Act, a disease of a kind specified in column 1 of an item of the table in Schedule 1 is a disease related to employment of a kind specified in column 2 of that item.


 

Schedule 1—Specification

 

 

Column 1

Column 2

Item

Disease

Employment

Infectious diseases

 

1          

Anthrax

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts.

2          

Brucellosis

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts; or

(d)     animal waste.

3          

Hepatitis A

Employment involving work with human waste.

4          

Hepatitis B or Hepatitis C

Employment involving work with human body fluids.

5          

Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)

Employment involving work with:

(a)     needles in a healthcare services setting; or

(b)     sharps in a healthcare services setting.

6          

Leptospirosis

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts; or

(d)     animal waste.

7          

Orf

Employment involving work with:

(a)     goats; or

(b)     goat carcasses; or

(c)     sheep; or

(d)     sheep carcasses.

8          

Q-fever

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts.

9          

Tuberculosis

Employment involving work with:

(a)     animals:

(i)    in a farming setting; or

(ii)   in a veterinarian setting; or

(b)     animal carcasses:

(i)    in a farming setting; or

(ii)   in a veterinarian setting; or

(c)     human corpses:

(i)    in a healthcare services setting; or

(ii)   in a mortuary setting; or

(d)     persons (individuals) in a healthcare services setting.

Malignant diseases

10      

Primary malignant disease of the salivary gland

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

11      

Primary malignant disease of the nasopharynx

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     formaldehyde; or

(b)     wood.

12      

Primary malignant disease of the oesophagus

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

13      

Primary malignant disease of the stomach

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

14      

Primary malignant disease of the colon or rectum

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

15      

Primary malignant disease of the liver

Employment for at least 5 years (whether consecutive or not) involving work with vinyl chloride monomer.

16      

Primary malignant disease of the nasal cavity or para-nasal sinuses

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     nickel; or

(d)     leather; or

(e)     wood.

17      

Primary malignant disease of the larynx

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material; or

(c)     acid mist (strong inorganic).

18      

Primary malignant disease of the lung caused by asbestos

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

19      

Primary malignant disease of the bone

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

20      

Primary malignant disease of the mesothelium

Employment for at least one year (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

21      

Primary malignant disease of the breast

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

22      

Primary malignant disease of the ovary

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

23      

Primary malignant disease of the kidney

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     trichloroethylene.

24      

Primary malignant disease of urothelial tissue lining the urinary tract

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     2-naphthylamine; or

(d)     benzidine; or

(e)     cyclophosphamide; or

(f)      ortho-toluidine; or

(g)     polycyclic aromatic hydrocarbons during aluminium production.

25      

Primary malignant disease of the brain

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

26      

Primary malignant disease of the thyroid

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

27      

Primary leukaemia (excluding chronic lymphatic leukaemia)

Employment for at least 2 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     benzene; or

(d)     butadiene; or

(e)     cyclophosphamide; or

(f)      formaldehyde.

28      

Primary non-Hodgkins lymphoma

Employment for at least 2 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

Diseases of the nervous system

29      

Parkinson’s disease

Employment for at least one year (whether consecutive or not) involving work with manganese.

30      

Peripheral neuropathy

Employment for at least one year (whether consecutive or not) involving work with:

(a)     acrylamide; or

(b)     arsenic; or

(c)     carbon disulphide; or

(d)     lead; or

(e)     mercury; or

(f)      n-hexane; or

(g)     organophosphates; or

(h)     trichloroethylene.

Respiratory diseases

 

31      

Occupational asthma

Employment for at least 4 weeks (whether consecutive or not) involving work with an agent or thing specified in column 2 of an item of the table in Schedule 2.

32      

Coal workers’ pneumoconiosis

Employment for at least 5 years (whether consecutive or not) involving work with coal.

33      

Asbestosis

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

34      

Silicosis

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     material containing crystalline silica; or

(b)     silica.

35      

Other pneumoconiosis

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     aluminium; or

(b)     barium; or

(c)     beryllium; or

(d)     cobalt; or

(e)     iron oxide; or

(f)      tin; or

(g)     tungsten.

36      

Byssinosis

Employment for at least 4 weeks (whether consecutive or not) involving work with:

(a)     unprocessed cotton; or

(b)     unprocessed flax; or

(c)     unprocessed hemp; or

(d)     unprocessed sisal.

37      

Extrinsic allergic alveolitis

Employment for at least 4 weeks (whether consecutive or not) involving work with:

(a)     feathers; or

(b)     grain; or

(c)     hay; or

(d)     straw.

Hepatic disease

38      

Non-infectious hepatitis

Employment involving work with:

(a)     acrylonitrile; or

(b)     alcohols; or

(c)     amino-derivatives of benzene; or

(d)     antimony; or

(e)     aromatic hydrocarbons; or

(f)      arsenic; or

(g)     benzene; or

(h)     benzoquinone; or

(i)       beryllium; or

(j)      cadmium; or

(k)     carbon disulphide; or

(l)       carbon monoxide; or

(m)   chromium; or

(n)     copper; or

(o)     fluorine; or

(p)     glycols; or

(q)     hexane; or

(r)      hydrogen cyanide; or

(s)      hydrogen sulphide; or

(t)      ketones; or

(u)     lead; or

(v)     manganese; or

(w)    mercury; or

(x)     methylene chloride; or

(y)     mineral acids; or

(z)     nitric acid esters; or

(za)         organochlorine compounds; or

(zb)         organophosphate; or

(zc)         osmium; or

(zd)         oxides of nitrogen; or

(ze)         ozone; or

(zf)          phosgene; or

(zg)         phosphorus; or

(zh)         selenium; or

(zi)          styrene; or

(zj)          thallium; or

(zk)         tin; or

(zl)          toluene; or

(zm)        toxic halogen derivatives of aliphatic; or

(zn)         toxic nitro-derivatives of benzene; or

(zo)         vanadium; or

(zp)         zinc.

Skin diseases

 

39      

Irritant contact dermatitis

Employment for at least 4 weeks (whether consecutive or not) involving work and contact with:

(a)     alcohols; or

(b)     cutting fluids; or

(c)     cleaners; or

(d)     degreasers; or

(e)     disinfectants; or

(f)      liquids (frequent contact); or

(g)     liquids (prolonged contact); or

(h)     petroleum products; or

(i)       soaps; or

(j)      solvents.

40      

Allergic contact dermatitis

Employment for at least 4 weeks (whether consecutive or not) involving work and contact with:

(a)     2,5-diaminotoluene sulfate; or

(b)     4-phenylenediamine base; or

(c)     ammonium persulfate; or

(d)     cobalt chloride; or

(e)     cocamide diethanolamide; or

(f)      coconut diethanolamide; or

(g)     colophonium/colophony/rosin; or

(h)     diazolidinyl urea; or

(i)       epoxy resin; or

(j)      formaldehyde; or

(k)     fragrance mix I:

(i)         amylcinnamaldehyde; or

(ii)        cinnamic alcohol; or

(iii)       cinnamic aldehyde;

(iv)       eugenol; or

(v)        geraniol; or

(vi)       hydroxycitronellal; or

(vii)      isoeugenol; or

(viii)     oakmoss absolute; or

(l)       fragrance mix II:

(i)         citral; or

(ii)        citronellol; or

(iii)       coumarin; or

(iv)       farnesol; or

(v)        hexyl cinnamic aldehyde; or

(vi)       hydroxyisohexyl 3-cyclohexene carboxaldehyde; or

(m)   glyceryl monothioglycolate; or

(n)     hydroxyethyl methacrylate; or

(o)     mercaptobenzothiazole; or

(p)     methyl chloroisothiazolinone; or

(q)     mixture of methylchloroisothiazolinone and methylisothiazolinone; or

(r)      nickel sulfate; or

(s)      potassium dichromate; or

(t)      quaternium 15; or

(u)     thiuram mix:

(i)         tetramethylthiuramdisulfide; or

(ii)        tetramethylthiuram monosulfide; or

(iii)       tetraethylthiuram disulfide.

41      

Occupational vitiligo

Employment for at least 4 weeks (whether consecutive or not) involving work with:

(a)     hydroquinone; or

(b)     monobenzyl ether of hydroquinone; or

(c)     monobutyl ether of hydroquinone; or

(d)     para-amylphenol; or

(e)     para-tertiary-butylcatechol; or

(f)      para-tertiary-butylphenol.

Musculoskeletal diseases

42      

Raynaud’s disease

Employment for at least 12 weeks (whether consecutive or not) involving work with:

(a)     powered equipment that produces vibration; or

(b)     powered tools that produce vibration.

43      

Bursitis at the elbow or knee

Employment for at least 6 months (whether consecutive or not) involving a work activity that:

(a)     for bursitis at the elbow:

(i)         involves prolonged external friction at or about the elbow; or

(ii)        involves prolonged external pressure at or about the elbow; or

(iii)       involves recurrent external friction at or about the elbow; or

(iv)       involves recurrent external pressure at or about the elbow; or

(b)     for bursitis at the knee:

(i)         involves prolonged external friction at or about the knee; or

(ii)        involves prolonged external pressure at or about the knee; or

(iii)       involves recurrent external friction at or about the knee; or

(iv)       involves recurrent external friction at or about the knee.

Acute diseases

44      

Acute poisoning or toxicity affecting the heart, lungs, liver, kidney, nervous system or blood

The same as for item 38.


 

Schedule 2—Occupational asthma

 

 

Column 1

Column 2

Item

Class of agent or thing

Specified agent or thing

1          

Arthropods

(a)     acarian; or

(b)     barn mite; or

(c)     caddisfly; or

(d)     cricket; or

(e)     Ephestia kuehniella (Mediterranean flour moth); or

(f)      fowl mite; or

(g)     fruit fly; or

(h)     grain mite; or

(i)       flour mite; or

(j)      lesser mealworm; or

(k)     locust; or

(l)       sheep blowfly; or

(m)   silkworm.

2          

Acids

(a)     dodecanedioic acid; or

(b)     glacial acetic acid; or

(c)     hydrochloric acid; or

(d)     peroxyacetic acid; or

(e)     sulphuric acid; or

(f)      sulphur dioxide.

3          

Acrylates

(a)     acrylic acid; or

(b)     cyanoacrylates; or

(c)     methyl methacrylate; or

(d)     polymethyl methacrylate; or

(e)     trimethylolpropane triacrylate/2-hydroxypropyl acrylate.

4          

Aldehydes

(a)     formaldehyde; or

(b)     gluteraldehyde; or

(c)     paraformaldehyde; or

(d)     urea formaldehyde.

5          

Amines

(a)     aminoethyl ethanolamine; or

(b)     diethanolamine; or

(c)     dimethylethanolamine; or

(d)     ethanolamines; or

(e)     ethylenediamine; or

(f)      monoethanolamine; or

(g)     surfactant-specific amines; or

(h)     triethanolamine; or

(i)       triethylenetetramine; or

(j)      trimethylhexane-1; or

(k)     6-diamine/isophorondiamine mixture.

6          

Ammonias

(a)     anhydrous ammonia; or

(b)     ammonium hydroxide; or

(c)     ammonia solution 10%; or

(d)     ammonia solution 29%.

7          

Anhydrides

(a)     hexahydrophthalic anhydride; or

(b)     himic anhydride; or

(c)     maleic anhydride; or

(d)     methyl tetrahydrophthalic; or

(e)     anhydride; or

(f)      phthalic anhydride; or

(g)     tetrachlorophthalic anhydride; or

(h)     trimellitic anhydride.

8          

Bio-aerosols

(a)     Alternaria; or

(b)     Chrysonilia sitophilia; or

(c)     Neurospora; or

(d)     Penicillium; or

(e)     cutting oils.

9          

Biological enzymes

(a)     Bacillus subtilis enzymes; or

(b)     bromelain; or

(c)     egg lysozyme; or

(d)     esperase; or

(e)     flaviastase; or

(f)      fungal amylase; or

(g)     fungal amyloglucosidase; or

(h)     fungal hemicellulose; or

(i)       pancreatin; or

(j)      papain; or

(k)     pepsin; or

(l)       trypsin.

10      

Epoxy

(a)     epoxy; or

(b)     epoxy adhesive.

11      

Ethylene oxide

ethylene oxide.

12      

Flours

(a)     buckwheat flour; or

(b)     rye flour; or

(c)     soya flour; or

(d)     wheat flour.

13      

Flowers

(a)     baby’s breath; or

(b)     freesia; or

(c)     Limonium tataricum; or

(d)     sunflower.

14      

Foods

(a)     Brazil ginseng; or

(b)     castor bean; or

(c)     chamomile; or

(d)     cinnamon; or

(e)     Dioscorea batatas (Chinese yam); or

(f)      egg protein; or

(g)     fenugreek; or

(h)     garlic dust; or

(i)       green beans; or

(j)      guar; or

(k)     hops; or

(l)       paprika; or

(m)   pectin; or

(n)     rose hips; or

(o)     soybean lecithin; or

(p)     tea; or

(q)     thiamine (vitamin B); or

(r)      thyme.

15      

Industrial cleaning and sterilising agents

(a)     alkyl dimethyl benzyl ammonium chloride; or

(b)     benzyl-C10-16-alkyldimethyl, chlorides; or

(c)     benzyl-C12-16-alkyldimethyl, chlorides; or

(d)     benzyl-C12-18-alkyldimethyl, chlorides; or

(e)     benzyl-C16-18-alkyldimethyl, chlorides; or

(f)      benzyldimethylstearyl ammonium chloride; or

(g)     cetalkonium chloride; or

(h)     chlorhexidine; or

(i)       chlorine; or

(j)      dialkyl methyl benzyl ammonium chloride; or

(k)     dicumyl-peroxide; or

(l)       dodecyl dimethyl ammonium chloride; or

(m)   dimethyl ethyl benzyl ammonium chloride; or

(n)     dodecyl-dimethylbenzylammonium; or

(o)     fluorine; or

(p)     n-alkyl dimethyl benzyl ammonium chloride; or

(q)     persulphate salts; or

(r)      sodium hypochlorite; or

(s)      sodium metabisulfite.

16      

Isocyanates

(a)     diisocyanates; or

(b)     hexamethylene diisocyanate prepolymers; or

(c)     isocyanates; or

(d)     toluene diisocyanate prepolymers.

17      

Latex

(a)     latex; or

(b)     natural rubber.

18      

Medications

(a)     ampicillin; or

(b)     amprolium; or

(c)     cimetidine; or

(d)     codeine; or

(e)     colistin; or

(f)      hydralazine; or

(g)     ipecacuanha; or

(h)     hydrocodone; or

(i)       isonicotinic acid hydrazide; or

(j)      methyldopa; or

(k)     morphine; or

(l)       opiate compounds; or

(m)   oxycodone; or

(n)     papaverine; or

(o)     penicillamine; or

(p)     penicillins; or

(q)     phenylglycine acid chloride; or

(r)      psyllium; or

(s)      salbutamol intermediate; or

(t)      spiramycin; or

(u)     tetracycline; or

(v)     thebaine; or

(w)    tylosin tartrate; or

(x)     vancomycin.

19      

Metals

(a)     aluminium; or

(b)     aluminium chloride; or

(c)     aluminium oxide; or

(d)     aluminium compounds; or

(e)     ammonium dichromate; or

(f)      ammonium hexachloroplatinate (IV); or

(g)     chromium; or

(h)     chromium, metal; or

(i)       chromium, hexavalent; or

(j)      chromium, non-hexavalent; or

(k)     cobalt; or

(l)       cobalt compounds; or

(m)   nickel; or

(n)     nickel compounds; or

(o)     platinum; or

(p)     rhodium; or

(q)     soluble halogenated platinum compounds; or

(r)      titanium oxide/dioxide; or

(s)      tributyl tin oxide; or

(t)      tungsten carbide; or

(u)     tungsten carbide/cobalt; or

(v)     vanadium; or

(w)    welding fumes – gas metal arc welding on uncoated mild steel; or

(x)     welding fumes – stainless steel; or

(y)     stainless steel; or

(z)     zinc oxide.

20      

Other reactive chemicals

(a)     chlorofluorocarbon refrigerants heated; or

(b)     fluoride; or

(c)     furfuryl alcohol mixed with a catalyst; or

(d)     isolyzer; or

(e)     polyethylene terephthalate/polybutylene terephthal; or

(f)      polyfunctional aziridine; or

(g)     polypropylene heated; or

(h)     polyvinyl chloride heated; or

(i)       polyvinyl chloride non-heated; or

(j)      polyvinyl chloride thermally degraded; or

(k)     radiographic fixative; or

(l)       resin containing furfuryl alcohol; or

(m)   styrene; or

(n)     trigylicidyl isocyanurate.

21      

Pesticides

(a)     3-amino-5-mercapto-1;2;4-triazole; or

(b)     acephate; or

(c)     chloramine T; or

(d)     chlorothalonil (bravo, echo); or

(e)     diazinon; or

(f)      dimethoate; or

(g)     fenthion; or

(h)     malathion; or

(i)       nemacur; or

(j)      piperazine; or

(k)     piperazine citrate; or

(l)       piperazine hydrochloride; or

(m)   pyrethrins; or

(n)     pyrfon; or

(o)     safrotin; or

(p)     tetramethrin.

22      

Plants and sensitising agents or irritants derived from plants

(a)     almond dust; or

(a)     Arabidopsis thaliana; or

(b)     Chlorella algae; or

(c)     gum arabic; or

(d)     henna; or

(e)     kapok; or

(f)      linseed oilcake; or

(g)     Pinellia ternata; or

(h)     quillaja bark; or

(i)       rice dust; or

(j)      tall oil crude; or

(k)     tall oil – rosin; or

(l)       tobacco leaf; or

(m)   tragacanth; or

(n)     turpentine; or

(o)     Vicia sativa (vetch); or

(p)     weeping fig.

23      

Reactive dyes

(a)     Cibachrome Brilliant Scarlet 32; or

(b)     Drimarene Brilliant Blue K-BL; or

(c)     Drimarene Brilliant Yellow K-3GL; or

(d)     Lanasol Yellow 4G; or

(e)     Levafix Brilliant Yellow E36; or

(f)      Methyl Blue; or

(g)     Rifacion Orange HE 2G; or

(h)     Rifafix Yellow 3 RN; or

(i)       Rifazol Black GR; or

(j)      Rifazol Brilliant Orange 3R.

24      

Sensitising agents or irritants derived from animals

(a)     bat guano; or

(b)     bovine serum albumin; or

(c)     casein; or

(d)     cat antigens; or

(e)     chicken antigens; or

(f)      cow antigens; or

(g)     frog antigens; or

(h)     guinea pig antigens; or

(i)       lactoserum; or

(j)      mice antigens; or

(k)     pig antigens; or

(l)       rabbit antigens; or

(m)   rat antigens.

25      

Sensitising agents or irritants derived from fish or shellfish

(a)     Anisakis simplex (herring worm) antigens; or

(b)     clam antigens; or

(c)     crab antigens; or

(d)     cuttlefish antigens; or

(e)     fishmeal; or

(f)      nacre dust; or

(g)     octopus antigens; or

(h)     prawn antigens; or

(i)       red soft coral antigens; or

(j)      salmon antigens; or

(k)     shrimp meal; or

(l)       trout antigens.

26      

Soldering fluxes

(a)     colophony soldering flux; or

(b)     alkyl aryl polyether soldering flux; or

(c)     zinc soldering flux.

27      

Wood

(a)     Triplochiton scleroxylon (African maple); or

(b)     Acacia melanoxylon (blackwood); or

(c)     Sequoia sempervirens (California redwood); or

(d)     Juglans olanchana (Central American walnut); or

(e)     Thuja occidentalis (eastern white cedar); or

(f)      Shoreal sp. (mahogany); or

(g)     Quercus robur (oak); or

(h)     Thuja lpicata (western red cedar).


 

Schedule 3—Repeals

Safety, Rehabilitation and Compensation (Specified Diseases) Notice 2007 (1)

1  The whole of the instrument

Repeal the instrument